SCHEMBL15969394

SCHEMBL15969394

CC(NC(=O)c1c(O)c(=O)n(C)c2ccccc12)c1cccc(N2CCC(O)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ACACB O00763 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
GAA P10253 1/20 0.41
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NLRP3 Q96P20 1/20 0.39
PHGDH O43175 1/20 0.39
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15969391 1.00 L3MBTL1 (0.55) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL15969835 0.91 L3MBTL1 (0.55) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL15969837 0.91 L3MBTL1 (0.55) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL14830490 0.88 L3MBTL1 (0.56) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL15969488 0.88 L3MBTL1 (0.56) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL14830813 0.88 L3MBTL1 (0.57) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL15969499 0.87 L3MBTL1 (0.54) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL15969583 0.87 L3MBTL1 (0.54) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL15969584 0.87 L3MBTL1 (0.54) L3MBTL1KMT2AMEN1POLBTDP1
SCHEMBL15969500 0.87 L3MBTL1 (0.54) L3MBTL1KMT2AMEN1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP claimed
EP-2760840-B1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-08-12 EP disclosed
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2015-04-16 US disclosed
US-8946430-B2 Quinolinone carboxamide inhibitors of endothelial lipase BRISTOL-MYERS SQUIBB COMPANY (US) 2015-02-03 US disclosed
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY 2014-08-28 US disclosed
US-7964748-B2 Process for preparing intermediates of HMG-CoA reductase inhibitors TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2011-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105376-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL L3MBTL1 3619/4885KMT2A 1068/4885MEN1 4291/4885
US-20140243314-A1 QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE LIPG, PNLIP, LPL L3MBTL1 3619/4885KMT2A 1068/4885MEN1 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.